Why TPST rose 48.3% on Sep 16 2026: cell therapy option
TPST+48.3%on Wed Sep 16 2026
Tempest Therapeutics, Inc. Common Stock was up 48.3% on the day at $1.12, ranked #5 on — its usual five-minute volume, when TapeRank recorded this spike at 04:01 ET during the pre-market session.
WHAT THE ROW LOOKED LIKE
LAST1.12
DAY▲ 48.3%
5 MIN▼ 2.61%
5M RVOL—
5M $VOL$504K
FLOAT*16.5M
RANK#5
SESSIONPRE-MARKET
* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
AI VERDICT
JUSTIFIEDCONFIDENCE4/5
TPST rose 56.2% after announcing an exclusive option to license Senlang’s CD7-targeted platform and in vivo CAR-T candidates, including a Phase 1 multiple-myeloma program. The catalyst expands its pipeline but remains an option agreement with no disclosed economics, while a recent $2.5 million placement adds substantial potential share issuance.
WHYA 56.2% move is broadly supported by a new oncology pipeline deal, but the unquantified option structure and early-stage assets make the reaction somewhat aggressive.
ANALYZED 04:01 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNA
FILINGS · 24H BEFORE THE MOVE
- 00:07 ETTempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's WhyBenzinga
- TUE 16:06 ETTempest Therapeutics Enters Into Exclusive Option Agreement To License Senlang's CD7-Targeted Lentiviral Vector Platform And Portfolio Of In Vivo CAR-T Product CandidatesBenzinga
- TUE 16:06 ET8-K — Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Statements and ExhibitsSEC 8-K
SESSION LEVELS AT CAPTURE
VWAP1.17
HOD1.21
LOD1.09
OR HIGH—
OR LOW—
PREV CLOSE0.7554
PM HIGH1.21
PM LOW1.09
GAP▲ 56.17% (indicated)
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO